人源抗matriptase-2抗体可限制β-地中海贫血小鼠的铁过载、α-珠蛋白聚集体和脾肿大
在Hbbth3/+β-地中海贫血小鼠中,每周给予全人源抗matriptase-2抗体RLYB331可诱导hepcidin表达、减少铁负荷、阻止毒性α-链/血红素聚集体形成并改善网织红细胞增多和脾肿大;RLYB331与RAP-536L联用完全逆转β-地中海贫血表型。
要点
- RLYB331每周给药可诱导hepcidin表达、降低铁负荷并减少α-珠蛋白聚集体。
- RAP-536L单用不预防铁过载,但可减少骨髓红系凋亡并改善贫血指标。
- RLYB331与RAP-536L联用完全逆转Hbbth3/+小鼠的β-地中海贫血表型。
核心结论
- RLYB331与RAP-536L联用完全逆转Hbbth3/+小鼠的β-地中海贫血表型,同时纠正铁过载、无效造血、脾肿大和血液学指标。
- 作者认为由RLYB331与luspatercept融合而成的多功能分子可能允许单药给药同时针对β-地中海贫血的不同病理生理方面。
研究设计与样本
- 在Hbbth3/+β-地中海贫血小鼠中测试全人源抗matriptase-2抗体RLYB331,该抗体阻断matriptase-2的蛋白酶活性。
- RLYB331每周给药;并进一步将RLYB331与RAP-536L联用,RAP-536L是含激活素受体IIB型胞外域的配体捕获蛋白。
主要发现
- RLYB331每周给药于Hbbth3/+小鼠诱导hepcidin表达、减少铁负荷、阻止毒性α-链/血红素聚集体形成、减少活性氧形成并改善网织红细胞增多和脾肿大。
- RAP-536L单用未预防铁过载,但显著减少骨髓红系群体凋亡、使红细胞计数正常化并改善血红蛋白和血细胞比容水平。
- RLYB331与RAP-536L联用完全逆转Hbbth3/+小鼠的β-地中海贫血表型并同时纠正铁过载、无效造血、脾肿大和血液学参数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron plays a major role in the deterioration of β-thalassemia. Indeed, the high levels of transferrin saturation and iron delivered to erythroid progenitors are associated with production of α-globin precipitates that negatively affect erythropoiesis. Matriptase-2/TMPRSS6, a membrane-bound serine protease expressed in hepatocytes, negatively modulates hepcidin production and thus is a key target to prevent iron overload in β-thalassemia. To address safety concerns raised by the suppression of Tmprss6 by antisense oligonucleotides or small interfering RNA, we tested a fully human anti-matriptase-2 antibody, RLYB331, which blocks the protease activity of matriptase-2. When administered weekly to Hbbth3/+ mice, RLYB331 induced hepcidin expression, reduced iron loading, prevented the formation of toxic α-chain/heme aggregates, reduced ros oxygen species formation, and improved reticulocytosis and splenomegaly. To increase the effectiveness of RLYB331 in β-thalassemia treatment even further, we administered RLYB331 in combination with RAP-536L, a ligand-trapping protein that contains the extracellular domain of activin receptor type IIB and alleviates anemia by promoting differentiation of late-stage erythroid precursors. RAP-536L alone did not prevent iron overload but significantly reduced apoptosis in the erythroid populations of the bone marrow, normalized red blood cell counts, and improved hemoglobin and hematocrit levels. Interestingly, the association of RLYB331 with RAP-536L entirely reversed the β-thalassemia phenotype in Hbbth3/+ mice and simultaneously corrected iron overload, ineffective erythropoiesis, splenomegaly, and hematological parameters, suggesting that a multifunctional molecule consisting of the fusion of RLYB331 with luspatercept (human version of RAP-536L) would allow administration of a single medication addressing simultaneously the different pathophysiological aspects of β-thalassemia.
引用
- Wake M, Palin A, Belot A, et al. A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice. Blood Adv. 2024. PMID: 38241484. doi:10.1182/bloodadvances.2023012010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。